JPMorgan Chase & Co. Boosts CVS Health (NYSE:CVS) Price Target to $111.00

CVS Health (NYSE:CVS) had its target price boosted by investment analysts at JPMorgan Chase & Co. from $101.00 to $111.00 in a report released on Tuesday, Marketbeat Ratings reports. The firm currently has an “overweight” rating on the pharmacy operator’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 13.10% from the company’s previous close.

A number of other brokerages also recently commented on CVS. Argus lowered their price objective on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, January 28th. Wall Street Zen upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Sanford C. Bernstein boosted their price target on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday. Piper Sandler dropped their price objective on shares of CVS Health from $101.00 to $99.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 31st. Finally, UBS Group lifted their price objective on shares of CVS Health from $97.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

CVS Health Stock Up 3.1%

CVS Health stock opened at $98.14 on Tuesday. The firm has a market capitalization of $125.22 billion, a P/E ratio of 43.24, a P/E/G ratio of 0.93 and a beta of 0.60. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. CVS Health has a twelve month low of $58.35 and a twelve month high of $98.22. The stock’s fifty day simple moving average is $78.07 and its 200-day simple moving average is $78.36.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same period last year, the business posted $2.25 earnings per share. CVS Health’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts expect that CVS Health will post 7.46 earnings per share for the current fiscal year.

Insider Buying and Selling at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On CVS Health

Several institutional investors have recently bought and sold shares of the company. Arvest Bank Trust Division lifted its stake in shares of CVS Health by 2,401.7% in the 1st quarter. Arvest Bank Trust Division now owns 66,945 shares of the pharmacy operator’s stock worth $4,808,000 after acquiring an additional 64,269 shares during the period. Daner Wealth Management LLC acquired a new position in shares of CVS Health during the first quarter worth about $194,000. First Citizens Bank & Trust Co. raised its holdings in CVS Health by 6.3% during the first quarter. First Citizens Bank & Trust Co. now owns 38,038 shares of the pharmacy operator’s stock worth $2,732,000 after purchasing an additional 2,266 shares in the last quarter. CI Investments Inc. lifted its position in CVS Health by 10.1% in the first quarter. CI Investments Inc. now owns 106,462 shares of the pharmacy operator’s stock valued at $7,646,000 after purchasing an additional 9,736 shares during the period. Finally, First Trust Advisors LP boosted its holdings in CVS Health by 4.2% in the 1st quarter. First Trust Advisors LP now owns 2,344,647 shares of the pharmacy operator’s stock valued at $168,393,000 after purchasing an additional 93,502 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts at JPMorgan and Sanford C. Bernstein raised their price targets on CVS Health, reinforcing confidence that the stock still has room to run after strong quarterly results. Analyst target raises and company news
• Positive Sentiment: CVS Health won Gold in Enterprise AI and Silver in Customer Experience AI at the 2026 Stevie Awards, highlighting continued progress in using technology to improve operations and customer service. CVS Health wins awards for AI innovation
• Positive Sentiment: MinuteClinic is expanding its clinically supervised weight-loss and preventive care offerings, which supports CVS’s broader strategy to grow higher-value healthcare services. MinuteClinic weight-loss program
• Positive Sentiment: Omnicare, a CVS subsidiary, received court approval to sell its business to GenieRx, removing uncertainty around a distressed asset and potentially simplifying CVS’s portfolio. Reuters Omnicare sale approval

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.